Paradigm Biopharmaceuticals Ltd (ASX: PAR) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Paradigm Biopharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $85.70 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 350.36 million
Earnings per share -0.233
Dividend per share N/A
Year To Date Return -42.35%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Paradigm Biopharmaceuticals Ltd (ASX: PAR)
    Latest News

    medical asx share price represented by doctor giving thumbs up
    Healthcare Shares

    Bell Potter says this ASX biotech stock could rocket 80%

    Investors with a high tolerance for risk may want to check out this stock.

    Read more »

    Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx
    Healthcare Shares

    3 ASX healthcare shares outperforming on quarterly updates

    These stocks are charging ahead on an otherwise lacklustre trading day.

    Read more »

    Man drawing an upward line on a bar graph symbolising a rising share price.
    Share Gainers

    Why Fiducian Group, Northern Star, Paradigm, and Santos shares are charging higher

    These shares are avoiding the market sell-off.

    Read more »

    Healthcare Shares

    Here's a 33c ASX stock that could have the potential to reach $1+

    Bell Potter is tipping huge returns for this small cap.

    Read more »

    Three guys in shirts and ties give the thumbs down.
    Share Fallers

    Why Core Lithium, New Hope, Paradigm, and Sayona Mining shares are sinking today

    These ASX shares are not having a very good session. But why?

    Read more »

    A young woman with long brown hair opens her green eyes widely expressing surprise.
    52-Week Lows

    Guess which ASX All Ords share is crashing 34% to a 52-week low

    This biopharmaceutical company's shares are being hammered on Wednesday. But why?

    Read more »

    A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
    Healthcare Shares

    3 ASX healthcare shares up 10% to 22% on news

    These healthcare shares are catching the eye on Wednesday. But why?

    Read more »

    Man raising both his arms in the air with a piggy bank on his lap, symbolising a record high.
    Healthcare Shares

    Guess which ASX healthcare share is rocketing 18% today

    Something is getting investors excited about this healthcare share today. What is it?

    Read more »

    Red arrow going down and symbolising a falling share price.
    Share Fallers

    Why Latin Resources, Paradigm, Sunland, and Weebit Nano shares are falling

    These ASX shares are having a tough time on Tuesday.

    Read more »

    A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
    Share Fallers

    Why Energy Resources, Paradigm, Piedmont Lithum, and Seek shares are dropping today

    These ASX shares are dropping into the red on Tuesday.

    Read more »

    A man clenches his fists in excitement as gold coins fall from the sky.
    Share Gainers

    Why Appen, Core Lithium, Paradigm, and Sayona Mining shares are racing higher

    These ASX shares are on form on Friday...

    Read more »

    A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
    Share Fallers

    Why Best & Less, Cettire, Life360, and Paradigm shares are sinking today

    These ASX shares are on the slide on Tuesday...

    Read more »

    Frequently Asked Questions

    No, Paradigm does not pay shareholder dividends at this time. 

    Paradigm Biopharmaceuticals Limited listed on the ASX on 19 August 2015.

    PAR ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Paradigm Biopharmaceuticals Ltd

    Paradigm Biopharmaceuticals Ltd (ASX: PAR) is a late-stage drug development company researching drug repurposing. The company seeks to identify and transform existing molecules to develop effective treatments for conditions with limited treatment options. Currently, more than 30% of therapies approved or launched globally represent drugs approved for new indications, reformulations, or new combinations of existing drugs.

    Paradigm's current commercial prospect is injectable pentosan polysulfate sodium (PPS, or brand name Zilosul®) in the treatment of osteoarthritis. PPS is FDA-approved and has a track record of treating inflammation including bladder condition cystitis and is used in the EU for preventing deep vein thrombosis. Paradigm has advanced to Phase 3 trial stage investigating PPS for osteoarthritis treatment. The company is based in Melbourne with offices in the US and Europe. 

    PAR Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    21 Jun 2024 $0.25 $0.02 8.70% 491,183 $0.23 $0.25 $0.23
    20 Jun 2024 $0.23 $0.01 4.55% 837,704 $0.23 $0.23 $0.21
    19 Jun 2024 $0.22 $-0.02 -8.51% 504,715 $0.24 $0.24 $0.22
    18 Jun 2024 $0.24 $0.00 0.00% 304,210 $0.24 $0.24 $0.24
    17 Jun 2024 $0.24 $0.00 0.00% 564,639 $0.24 $0.24 $0.23
    14 Jun 2024 $0.24 $0.00 0.00% 474,504 $0.24 $0.24 $0.23
    13 Jun 2024 $0.23 $-0.01 -4.17% 748,890 $0.25 $0.25 $0.23
    12 Jun 2024 $0.24 $0.00 0.00% 292,038 $0.24 $0.24 $0.24
    11 Jun 2024 $0.24 $-0.01 -4.08% 659,985 $0.25 $0.25 $0.24
    07 Jun 2024 $0.25 $0.00 0.00% 126,961 $0.25 $0.25 $0.25
    06 Jun 2024 $0.25 $-0.01 -4.00% 380,356 $0.25 $0.25 $0.25
    05 Jun 2024 $0.25 $0.00 0.00% 370,181 $0.25 $0.26 $0.25
    04 Jun 2024 $0.25 $0.00 0.00% 279,930 $0.26 $0.26 $0.25
    03 Jun 2024 $0.25 $0.00 0.00% 873,101 $0.25 $0.28 $0.25
    31 May 2024 $0.25 $0.00 0.00% 409,567 $0.25 $0.26 $0.25
    30 May 2024 $0.25 $-0.01 -3.92% 372,677 $0.26 $0.26 $0.25
    29 May 2024 $0.26 $-0.01 -3.85% 238,174 $0.27 $0.27 $0.26
    28 May 2024 $0.26 $-0.01 -3.77% 259,522 $0.27 $0.27 $0.26
    27 May 2024 $0.27 $0.01 3.92% 445,090 $0.27 $0.27 $0.26
    24 May 2024 $0.26 $0.01 4.08% 282,719 $0.25 $0.26 $0.25

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    29 Feb 2024 Paul Rennie Issued 1,200,000 $420,000
    As advised by the company. Employee Performance Rights Plan, 1,200,000 Rights
    29 Feb 2024 Donna Skerrett Issued 1,000,000 $350,000
    As advised by the company. Employee Performance Rights Plan
    30 Nov 2023 Helen Fisher Issued 1,021 $438
    Rights issue.
    30 Nov 2023 Helen Fisher Issued 766 $298
    Rights issue.
    30 Nov 2023 Paul Rennie Issued 466,000 $200,380
    Rights issue.
    30 Nov 2023 Paul Rennie Sell 300,000 $117,000
    As advised by the company. Employee shares buy-back
    30 Nov 2023 Paul Rennie Issued 349,500 $136,305
    Rights issue.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Paul Rennie Executive DirectorManaging DirectorExecutive Chairman May 2014
    Mr Rennie has sales, marketing, business development, operational and IP commercialisation experience in the biopharmaceutical sector. Paul's experience includes working for Boehringer Mannheim (now Roche Diagnostics), Merck KGGA as national sales and marketing manager and Soltec (FH Faulding Ltd) as their Director of business development. Paul also led the commercialisation of Recaldent, a novel biopharmaceutical arising from research at the dental school, University of Melbourne. Paul took an R&D project from the laboratory bench to a commercial product now marketed globally as an additive to oral care products. More recently Paul worked in a number of positions with Mesoblast Ltd. Paul was the inaugural COO and moved into Executive Vice President New Product Development for the adult stem cell company. Paul is the founder of Paradigm Biopharmaceuticals.
    Mr Amos Meltzer Non-Executive Director Dec 2020
    Mr Meltzer has over 25 years of experience in international trade and in commercialising technologies, principally in the life sciences sector. He has presided over life science research and product development projects clinical trials as well as the commercialisation of life sciences assets through both licensing and the sale and marketing of a pharmaceutical product. Previously Amos served as General Counsel and IP director at two Nasdaq-listed companies, Compugen and Gilat, as a Non-Executive Director of a biotechnology company Evogene, and as VP of Business Development and then CEO of an ASX-listed biopharmaceutical company Immuron. Amos currently serves as Chief Legal Officer of neuro-medical device company Synchron, chairman of the Board of surgeons' education services company Vasculab, and as a legal adviser to a number of ASX listed and private life science companies. Amos Risk Management Committee.
    Dr Donna Skerrett Executive Director Jul 2020
    Dr Donna Skerrett has more than 30 years' experience in transfusion medicine, cellular therapy, and transplantation. She brings a wealth of experience in medical, clinical, and regulatory affairs. Donna served previously as Chief Medical Officer at Mesoblast. She was Director of Transfusion Medicine and Cellular Therapy at Weill Cornell Medical Center in New York (2004 - 2011), and prior to that was Associate Director of Transfusion Medicine and Director of Stem Cell Facilities at Columbia University's New York-Presbyterian Hospital. She has previously chaired the New York State Council on Blood and Transfusion Services, and served on the Board of Directors of the Fox Chase Cancer Center in Philadelphia, PA, and is currently a member of the Board of Visitors of Lewis Katz School of Medicine at Temple University.
    Mr Matthew James Fry Non-Executive Director Mar 2024
    Mr Fry joins the Paradigm board with more than 25 years in business creation, strategy, and expansion in healthcare and medical diagnostics globally. He is currently the CEO, Managing Director and Founder of AM Diagnostics Pty Ltd, a manufacturer and distributor of world class medical diagnostic products. With his global network within the biotechnology and medical diagnostic industry, Matthew brings both entrepreneurial spirit and substantial experience in product commercialisation. As CEO of AM Diagnostics during the COVID pandemic. Matthew has experience with global regulatory agencies, in particular the Australian TGA and US FDA.
    Ms Abby Macnish Interim Company Secretary Aug 2022
    -
    Abby Macnish Interim Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hsbc Custody Nominees Australia Limited 19,967,193 7.09%
    Citicorp Nominees Pty Limited 15,408,992 5.47%
    Kzee Pty Ltd <Kzee Superannuation Fund A/C> 10,914,902 3.87%
    Mr Paul John Rennie 8,500,548 3.02%
    J P Morgan Nominees Australia Pty Limited 7,907,224 2.81%
    Netwealth Investments Limited <Wrap Services A/C> 7,199,417 2.56%
    Bnp Paribas Noms Pty Ltd <Drp> 6,307,738 2.24%
    Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 5,724,948 2.03%
    Wacc Pty Ltd <Progessive Global Fund A/C> 3,959,480 1.41%
    Nancy Edith Wilson Ghosh <Ghosh Family A/C> 3,475,835 1.23%
    Mr Evan Philip Clucas & Ms Leanne Jane Weston <Kuranga Nursery Super A/C> 3,207,913 1.14%
    Bnp Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> 2,616,142 0.93%
    Mr Brett Langan 2,303,432 0.82%
    V Redford Pty Ltd <Redford S/F A/C> 2,228,500 0.79%
    Hsbc Custody Nominees (Australia) Limited A/C 2 1,666,793 0.59%
    Australian Executor Trustees Limited <No 1 Account> 1,603,641 0.57%
    Ubs Nominees Pty Ltd 1,539,064 0.55%
    39Kp Pty Ltd <Ross Family A/C> 1,468,994 0.52%
    Ms Lenna Yu Ling Tye 1,441,631 0.51%
    Flinders Medical Centre Foundation 1,420,000 0.50%

    Profile

    since

    Note